Affimed
AFMD
$5.03
Share price
3.07%
Change (1 day)
458.89%
Change (1 year)
Categories
Affimed (AFMD) - Cash on Hand
Cash on Hand as of September 2023 : $0.10 B
According to Affimed
's latest financial reports the company has $0.10 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Affimed - Cash on Hand chart (from 2013 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.20 B | -8.95% |
| 2021-12-31 | $0.22 B | 23.91% |
| 2020-12-31 | $0.18 B | 54.84% |
| 2019-12-31 | $0.11 B | -6.28% |
| 2018-12-31 | $0.12 B | 160.27% |
| 2017-12-31 | $47.82 M | 1.19% |
| 2016-12-31 | $47.25 M | -43.68% |
| 2015-12-31 | $83.9 M | 73.67% |
| 2014-12-31 | $48.31 M | 742.8% |
| 2013-12-31 | $5.73 M | -11.59% |
| 2012-12-31 | $6.48 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | $0.75 B | 629.54% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | $18.87 M | -81.67% | 🇺🇸 USA |
 Agenus
AGEN | $76.11 M | -26.10% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $32.46 M | -68.47% | 🇺🇸 USA |